Latest News-Jiangsu Alphamab Biopharmaceuticals Co.,Ltd Mediaroom_Page

Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046

* ENREACH-LUNG-01 is a multi-center, randomized, double-blind, placebo-controlled phase III clini...

2021-10-18 10:19 2113

Alphamab Oncology Reports 2021 Interim Results and Business Highlights

SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), announced the...

2021-08-30 10:51 3566

Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China

SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced toda...

2021-08-24 15:08 2259

Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA

SUZHOU, China, June 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the ...

2021-06-30 08:55 8370

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021

SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data ...

2021-06-07 10:11 6391

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021

* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical...

2021-06-07 10:10 6019

Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021

* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in th...

2021-06-07 09:53 5577

Poster to Highlight ENVASARC Pivotal Trial of Envafolimab (KN035) will be presented at the 2021 ASCO Annual Meeting

SUZHOU, China, May 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the s...

2021-05-24 08:54 5581

Alphamab Oncology to Present Multiple Clinical Research Data at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021)

SUZHOU, China, May 20, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, data...

2021-05-20 09:34 8567

Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib)

SUZHOU, China, April 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced that...

2021-04-29 08:00 4468

Alphamab Oncology Presented Clinical Data of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at AACR 2021

SUZHOU, China, April 13, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2021-04-13 08:15 4060

Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights

SUZHOU, China, March 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), reported fin...

2021-03-23 23:08 4115

Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.

SUZHOU, China, March 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2021-03-09 20:00 3280

Alphamab Oncology announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KN046 for the treatment of thymic epithelial tumor

SUZHOU, China, Sept. 3, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that...

2020-09-03 23:46 2081

Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody

SUZHOU, China, June 9, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that ...

2020-06-10 08:40 5757

Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer

SUZHOU, China, June 8, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) a clinical stag...

2020-06-09 10:10 5663

Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China

SUZHOU, China, March 30, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced toda...

2020-03-30 19:00 3240

Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)

SUZHOU, China, March 27, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced toda...

2020-03-27 19:00 4130

Alphamab Oncology Announces Completion of US$60 Million Series B Financing

SUZHOU, China, May 28, 2019 /PRNewswire/ -- Alphamab Oncology, a leading biopharmaceutical company ...

2019-05-28 19:02 2635